Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis

被引:14
作者
Barabas, AZ
Cole, CD
Barabas, AD
Lafreniere, R
机构
[1] Univ Calgary, Dept Surg, Hlth Sci Ctr, Calgary, AB T2N 4N1, Canada
[2] Univ Utah, Dept Neurosurg, Salt Lake City, UT USA
关键词
autoimmunity; downregulation; nephritis; non-pathogenic IgM autoantibody; pathogenic IgG autoantibody;
D O I
10.1111/j.1440-1827.2006.01944.x
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
The purpose of the study was to find out if a new modified vaccination technique would be effective in downregulating immunopathological events during the course of an experimental autoimmune kidney disease (which is morphologically and functionally similar to Heymann nephritis) called 'slowly progressive Heymann nephritis' (SPHN). We have shown that the pathogenic IgG autoantibody (aab)-induced experimental autoimmune kidney disease process can be downregulated early on as well as during the chronic progressive phase, when rats were restimulated. The IgM aab, resulting from stimulation by immune complexes made up of rat kidney fraction 3 (rKF3) antigen and rat anti-rKF3 IgM antibody in antigen excess (MIC), can greatly diminish pathogenic aab production by removing or blocking nephritogenic antigens. Reduced IgG aab production limits the formation of damaging immune complexes (IC) in the glomeruli and development of proteinuria. At the end of the experiment 60% and 80% of the MIC-treated groups had no pathogenic IgG aab in their circulation, while all the untreated SPHN rats had high levels of IgG aab associated with disease progression manifesting in increased proteinuria and severe immune complex glomerulonephritis.
引用
收藏
页码:181 / 190
页数:10
相关论文
共 36 条
[1]
Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease [J].
Aruffo, A ;
Hollenbaugh, D .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (06) :683-686
[2]
AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154
[3]
Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model [J].
Barabas, AZ ;
Cole, CD ;
Barabas, AD ;
Lafreniere, R .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2004, 85 (06) :321-334
[4]
Production of Heymann nephritis by a chemically modified renal antigen [J].
Barabas, AZ ;
Cole, CD ;
Barabas, AD ;
Lafreniere, R .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2004, 85 (05) :277-285
[5]
Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats [J].
Barabas, AZ ;
Cole, CD ;
Barabas, AD ;
Cowan, JM ;
Yoon, CS ;
Waisman, DM ;
Lafreniere, R .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2004, 85 (04) :201-212
[6]
BARABAS AZ, 1969, CLIN EXP IMMUNOL, V4, P345
[7]
BARABAS AZ, 1969, CLIN EXP IMMUNOL, V5, P419
[8]
Production of a new model of slowly progressive Heymann nephritis [J].
Barabas, AZ ;
Cole, CD ;
Barabas, AD ;
Lafreniere, R .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2003, 84 (06) :245-258
[9]
BARABAS AZ, 1970, BRIT J EXP PATHOL, V51, P541
[10]
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand [J].
Bielekova, B ;
Goodwin, B ;
Richert, N ;
Cortese, I ;
Kondo, T ;
Afshar, G ;
Gran, B ;
Eaton, J ;
Antel, J ;
Frank, JA ;
McFarland, HF ;
Martin, R .
NATURE MEDICINE, 2000, 6 (10) :1167-1175